ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ORKA / dividends
LNTH (76) NEOG (47) CLDX (29) NTLA (25) ⌘ Pro Terminal →

Oruka Therapeutics Inc. (ORKA) Dividend Safety Gauge & 10-Year DRIP Compounder

$95.43 -1.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $94.99

Oruka Therapeutics Inc. (ORKA) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $6.41B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORKA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORKA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Oruka Therapeutics Inc. (NASDAQ: ORKA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $95.43 (-1.49% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ORKA ranks #226 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORKA compare to LNTH and NEOG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ORKA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.8%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORKA?
▼

Per ORKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000907654), Oruka Therapeutics Inc. generated $341.7M in revenue (+38.5% YoY), -$105.4M in net income, and -$88.4M in free cash flow against $488.6M in total assets and $7.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $94.99 (-0.46%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Cash (7)Whales (17)SEC (14)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
$121 Bull$93 Base$73 Bear
📬 FREE ORKA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORKA)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY ORKA SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (32% of score)

20D Institutional Volume Accumulation (±10.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$76.68+4.2% Next Q
Q2 (-2Q)
48
Grade D$79.92+20.1% Next Q
Q3 (-1Q)
50
Grade C-$95.97-0.6% Next Q
Current
53
Grade D+$95.43-0.9% Hist 90D α
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORKA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORKA currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($88.03) and Max Pain ($100.20) forces dealer call-delta covering toward $121.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORKA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ORKA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORKA)

  • ✓Walkthrough of ORKA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ORKA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.59%⚡ TESTING RESISTANCE
2026-11-03O $96.65H $96.87L $95.43C $95.43VOL 634.1K
RES: $97.55SUP: $64.39SMA50: $88.03SMA200: $70.19
$121.4$96.91$72.37$47.83$23.30RES $97.55SUP $64.39$95.432026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORKA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORKA Butterfly Map → + Track ORKA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
21.4%/yr Implied 5Y Growth

vs. +38.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ORKA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORKA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ORKA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORKA)

Health Care Rank #226 of 1015 ⚔️ LNTH vs ORKA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORKA vs. LNTH, NEOG, CLDX, NTLA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Oruka Therapeutics Inc. (ORKA) ranks #226 by composite RQD confidence (53/100, grade D+) and #139 by equity capitalization ($6.41B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with ORKA at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ORKA ACTIVE
Oruka Therapeutics Inc.
D+ 53/100 — — -18.8% -1.49% $6.41B Benchmark Subject
LNTH
Lantheus Holdings Inc.
B+ 76/100 28.0x 61.1% 20.3% -0.15% $6.56B /lnth-vs-orka →
NEOG
Neogen Corporation
D 47/100 — 46.9% -0.6% 0.00% $2.58B /neog-vs-orka →
CLDX
Celldex Therapeutics Inc.
E 29/100 — 87.1% -35.0% -3.52% $2.36B /cldx-vs-orka →
NTLA
Intellia Therapeutics Inc.
E 25/100 — — -35.0% -6.50% $1.75B /ntla-vs-orka →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000907654 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oruka Therapeutics Inc. (ORKA) reported GAAP revenue of $341.7M (+38.5% vs. FY2024 revenue of $246.7M , and +1572.8% cumulative change since FY2023) , GAAP net income of -$105.4M, operating cash flow of -$88.2M, and free cash flow of -$88.4M (-52.4% YoY). On the balance sheet, ORKA closed FY2025 with $488.6M in total assets against $7.5M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $341.7M -$105.4M -$88.2M -$88.4M $488.6M $7.5M
FY2024 (FY) 2024-12-31 $246.7M -$83.7M -$57.8M -$58.0M $396.0M $6.2M
FY2023 (FY) 2023-12-31 $20.4M -$5.3M -$5.0M -$5.0M $3.52B $823.6M

3. ORKA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORKA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Oruka Therapeutics Inc. (NASDAQ: ORKA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $95.43 (-1.49% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ORKA ranks #226 in composite RQD confidence.

How does ORKA compare to LNTH and NEOG in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ORKA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.8%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ORKA?

Per ORKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000907654), Oruka Therapeutics Inc. generated $341.7M in revenue (+38.5% YoY), -$105.4M in net income, and -$88.4M in free cash flow against $488.6M in total assets and $7.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ORKA trading relative to its 50-day, 200-day, and 52-week technical levels?

ORKA last traded at $95.43 (-1.49% on volume of 654,389 shares), positioning the stock +8.41% above its 50-day simple moving average ($88.03) and +35.96% above its 200-day simple moving average ($70.19). Across its 52-week range of $25.23 to $115.52, ORKA sits at the 77.7% percentile with a 14-day RSI of 67.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.3% ($85.60 to $105.26).

Direct Sub-Reports: ORKA RQD Cockpit ORKA 12M Forecast ORKA Earnings & Move ORKA Dividends & DRIP ORKA Insiders & 13F ORKA Whale Options ORKA Profit Sankey ORKA News & Why
ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

ORKA — Oruka Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Oruka Therapeutics Inc. (ORKA) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $95.43 (-1.49% 1D, market capitalization $6.41B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -18.8%, gross margin of —, operating margin of -6.8%, and free cash flow yield of -1.38%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.13x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 4/9, and Debt/Equity of 0.01x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Oruka Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under the industry Biotechnology: In Vitro & In Vivo Diagnostic Substances. Gross margin is recorded as 0% in the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Oruka Therapeutics Inc. (ORKA) reported $341.7M in annual revenue (up from $246.7M in FY2024, +38.5% YoY) and -$105.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.4M revenue, -$5.3M net income) through FY2025, ORKA scaled operating cash flow to -$88.2M and free cash flow to -$88.4M, backed by $488.6M in total assets against $7.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -1.38% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $25.23 – $115.52 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -6.8% operating margins and a 1.13x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), ORKA carries a macro regime beta of 1.13 and gross margin of —.

  • Key Question #1: Can ORKA sustain or expand its -6.8% operating margin and -18.8% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $341.7M and free cash flow of -$88.4M, how will capital allocation balance growth reinvestment against $7.5M in total debt?
  • Key Question #3: How sensitive is ORKA's 28.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.13x)?

ORKA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oruka Therapeutics Inc. (ORKA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORKA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORKA Bull vs. Bear Conversation Board — What's Your Call at $95.43?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORKA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ORKA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $112.37 (+16.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 17 of 20 in the RQD rating, with a low debt/equity ratio of 0.01 supporting th

Picked up a starter position in ORKA in my $100K Virtual Cash book at $96.87. Institutional accumulation and options positioning score 17 of 20 in the RQD rating, with a low debt/equity ratio of 0.01 supporting the balance sheet.. Trading inside a $25.23–$115.52 52-week range with -1.38% FCF yield gives solid downside support if Biotechnology: In Vitro & In Vivo Diagnostic Substances multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@CashFlowKing Agree on the RQD 53/100 quality, though with 1.13 beta I'm scaling in with half-size at $96.87 and keeping dry powder in case we test $90.09.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $73.62 (-24.0%)
Spot @ $96.87

Negative free cash flow of -$88.4M in FY 2025 against $46.9M of cash, with EPS (TTM) of -1.59 and ROIC of -18.8%.

Negative free cash flow of -$88.4M in FY 2025 against $46.9M of cash, with EPS (TTM) of -1.59 and ROIC of -18.8%.. Look at the math on ORKA: paying 28.0x forward P/E for -18.8% ROIC and -6.8% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $85.25 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%